What are Inherited Retinal Diseases (IRDs)?
Inherited retinal diseases are a group of eye conditions that run in families and slowly damage the retina, the light-sensing layer at the back of the eye. There are more than 50 types, including retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis. Most are caused by a single faulty gene, which leads to gradual vision loss over time.
Why Gene Therapy matters?
Because many IRDs are caused by one broken gene, doctors and scientists can try to fix or replace that gene. This is called gene therapy. Instead of only managing symptoms, gene therapy aims to slow down or stop the disease itself. For families, this offers real hope for preserving or improving vision.
The only approved Gene Therapy today: Luxturna
Right now, there is only one approved gene therapy for an IRD in Australia and worldwide: a treatment called Luxturna (voretigene neparvovec).
- Who it helps: People with a specific change in the RPE65 gene, which causes certain types of Leber congenital amaurosis or retinitis pigmentosa.
- How it works: A tiny, harmless virus carries a working copy of the RPE65 gene into the retina during a short eye surgery.
- Results: In studies, about two out of three patients saw better in dim light and could move around more easily, especially if treated earlier.
- Availability in Australia: Approved by the TGA in 2020, but only a small number of Australians have received it so far because the condition is rare and eligibility is strict.
What’s coming next: Trials and new treatments
Although only one therapy is approved, many more are being tested in clinical trials around the world, including for Australian patients.
Examples include:
- X-linked retinitis pigmentosa: Trials are testing gene therapy to replace the RPGR gene.
- CEP290-related LCA (LCA10): New medicines (antisense therapies) aim to correct the effect of a common gene mistake.
- Other IRDs: Trials are underway for Juvenile X-Linked Retinoschisis, Stargardt disease (ABCA4 retinopathy), Choroideremia, Achromatopsia, and Usher syndrome.
- Gene-agnostic treatments: Some therapies aim to protect retinal cells no matter which gene is faulty, helping a wider group of patients.
Australian eye specialists take part in these studies and can advise families on whether a trial might be suitable.
Future possibilities: Gene Editing and Cell Therapies
Scientists are also working on next-generation approaches:
- CRISPR gene editing: This technology could directly repair the faulty gene inside a person’s cells. It is still in early stages for eye disease and not yet approved for routine use.
- Optogenetics: For advanced disease, researchers are trying to make other retinal cells sensitive to light, acting like new “light detectors.”
- Cell therapies: Early trials are testing the idea of replacing damaged retinal cells with healthy lab-grown ones.
These options are not available yet but could expand choices in the future, even for people without a single clear gene target.
What families can do now
While waiting for more treatments, there are practical steps families can take:
- Get genetic testing: Knowing the exact gene change helps doctors confirm the diagnosis and check eligibility for trials or future therapies.
- See a Ocular genetics specialist regularly: Ongoing care helps monitor vision, manage complications, and keep you informed about new options.
- Join a registry: Programs like the Australian Inherited Retinal Disease Registry help match patients with relevant research and trials.
- Use low-vision support: Services such as low-vision clinics, assistive devices, and school or workplace adjustments can greatly improve daily life, regardless of trial access.
Looking ahead: Hope on the horizon
Luxturna shows that gene therapy for IRDs is real, not just an idea. With many trials in progress and new approaches like gene editing and cell therapy on the way, the next 5–10 years are likely to bring more options for more people.
For families today, the best approach is to stay informed, keep regular appointments with an eye specialist, and ask about genetic testing and research opportunities. This positions you to benefit as science continues to move forward.
